Improving cytokine-induced killer cell expansion using a gas-permeable culture method for clinical-scale production
Supannikar Tawinwung,1,7 Suparat Tudsamran,2,7 Rattapoom Thaiwong,2,7 Thiti Asawapanumas,3 Kitsada Wudhikarn,3,7 Chantiya Chanswangphuwana,3,7 Nattiya Hirankarn,4,5 Udomsak Bunworasate,3 Koramit Suppipat6,7
1 Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
2 Clinical Excellence Center for Comprehensive Cancer, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
3 Division of Hematology and Research Unit in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
4 Cancer Immunotherapy Excellence Center, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
5 Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Chulalongkorn University, Bangkok, Thailand
6 Department of Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
7 Cellular Immunotherapy Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Abstract
Background: Cytokine-induced killer (CIK) cells are a heterogeneous group of immune cells that exert potent MHC-unrestricted cytotoxicity toward various cancer cells in both solid and hematological malignancies.
Objective: The purposes of this study were to compare the expansion and characteristics of cytokine-induced killer cells between a standard culture method and a gas-permeable culture method and to develop a clinical-scale expansion protocol for cytokine-induced killer cells using a gas-permeable culture method.
Methods: We compared the absolute cell number, fold change, cell subsets, activation markers, cytokine concentrations, and cytotoxicity toward myeloid leukemia cell lines between cytokine-induced killer cells expanded using two different culture methods. Then, we determined the ability to achieve clinical-scale expansion of cytokine-induced killer cells using the gas-permeable culture method.
Results: Cytokine-induced killer cells in the gas-permeable culture method group exhibited significantly better expansion but maintained similar cell subsets, activation markers, and cytotoxicity to those in the standard culture method group. In addition, we successfully manufactured cytokine-induced killer cells for clinical use using the gas-permeable culture method. We also showed the clinical efficacy of allogeneic cytokine-induced killer cells produced by the gas-permeable culture method in a patient with acute myeloid leukemia that relapsed after allogeneic hematopoietic stem cell transplantation. This patient maintained ongoing disease remission for 2 years with minimal side effects after cytokine-induced killer cell infusion.
Conclusion: We successfully developed a simple and effective protocol for the ex vivo expansion of cytokine-induced killer cells using the gas-permeable culture method for clinical application.
Key words: Cytokine-induced killer cell, gas-permeable culture, acute myeloid leukemia, adoptive cellular therapy, clinical-scale expansion